Vigil Neuroscience (VIGL) Competitors

Vigil Neuroscience (NASDAQ:VIGL) and ChromaDex (NASDAQ:CDXC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Does the MarketBeat Community prefer VIGL or CDXC?

ChromaDex received 514 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 83.78% of users gave Vigil Neuroscience an outperform vote while only 64.50% of users gave ChromaDex an outperform vote.

Company	Underperform	Outperform
Vigil Neuroscience	Outperform Votes 31 83.78%	Underperform Votes 6 16.22%
ChromaDex	Outperform Votes 545 64.50%	Underperform Votes 300 35.50%

Is VIGL or CDXC more profitable?

ChromaDex has a net margin of 1.62% compared to Vigil Neuroscience's net margin of 0.00%. ChromaDex's return on equity of 4.85% beat Vigil Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vigil Neuroscience	N/A	-83.89%	-65.34%
ChromaDex	1.62%	4.85%	2.70%

Do analysts recommend VIGL or CDXC?

Vigil Neuroscience presently has a consensus price target of $19.75, suggesting a potential upside of 551.82%. ChromaDex has a consensus price target of $8.00, suggesting a potential upside of 47.60%. Given Vigil Neuroscience's higher probable upside, analysts clearly believe Vigil Neuroscience is more favorable than ChromaDex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vigil Neuroscience	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
ChromaDex	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders believe in VIGL or CDXC?

83.6% of Vigil Neuroscience shares are owned by institutional investors. Comparatively, 15.4% of ChromaDex shares are owned by institutional investors. 33.0% of Vigil Neuroscience shares are owned by company insiders. Comparatively, 9.6% of ChromaDex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the media refer more to VIGL or CDXC?

In the previous week, Vigil Neuroscience and Vigil Neuroscience both had 1 articles in the media. ChromaDex's average media sentiment score of 0.54 beat Vigil Neuroscience's score of 0.00 indicating that ChromaDex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vigil Neuroscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ChromaDex	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, VIGL or CDXC?

Vigil Neuroscience has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, ChromaDex has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.

Which has stronger valuation and earnings, VIGL or CDXC?

ChromaDex has higher revenue and earnings than Vigil Neuroscience. Vigil Neuroscience is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vigil Neuroscience	N/A	N/A	-$82.64M	-$2.06	-1.47
ChromaDex	$83.57M	4.95	-$4.94M	$0.01	542.54

Summary

ChromaDex beats Vigil Neuroscience on 10 of the 15 factors compared between the two stocks.